<sup>18</sup>F-FDG PET/CT基线SUV<sub>max</sub>在滤泡性淋巴瘤侵袭性、分期评价中的价值及其与中期疗效的相关性研究

戴云秀; 杨光杰; 王振光; 赵钰鋆; 于明明; 李大成; 武凤玉; 刘思敏; 戴云秀; 杨光杰; 王振光; 赵钰鋆; 于明明; 李大成; 武凤玉; 刘思敏

doi:10.3760/cma.j.issn.1673-4114.2018.02.002

[1]

中华医学会血液学分会, 中国抗癌协会淋巴瘤专业委员会.中国滤泡性淋巴瘤诊断与治疗指南(2013年版)[J].中华血液学杂志, 2013, 34(9):820-824. DOI:10.3760/cma.j.issn.0253-2727. 2013. 09.020.
Chinese Society of Hematology, Chinese Medical Association, Chinese Society of Lymphoma, Chinese Anti-cancer Association. Chinese guidelines for diagnosis and treatment of follicular lymphoma(2013)[J]. Chin J Hematol, 2013, 34(9):820-824. doi: 10.3760/cma.j.issn.0253-2727.2013.09.020

[2]

叶琇锦, 钱文斌.滤泡性淋巴瘤预后和分层治疗策略[J].中国实用内科杂志, 2015, 35(2):99-101. DOI:10.7504/nk2015010105.
Ye XJ, Qian WB. The current prognostic tools and strategy for treating follicular lymphoma[J]. Chin J Pract Intern Med, 2015, 35(2):99-101. doi: 10.7504/nk2015010105

[3]

Mendez M, Torrente M, Provencio M. Follicular lymphomas and their transformation:Past and current research[J]. Expert Rev Hematol, 2017, 10(6):515-524. DOI:10.1080/17474086.2017.1326812.

[4]

Yang G, Nie P, Wang Z, et al. ¹⁸F-FDG hepatic superscan caused by a non-germinal center subtype of diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2016, 43(10):1928. DOI:10.1007/s00259-016-3399-0.

[5]

刘青青, 王振光, 王楠, 等.非霍奇金淋巴瘤与广泛淋巴结转移癌的¹⁸F-FDG PET/CT淋巴结影像特征比较[J].中华核医学与分子影像杂志, 2016, 36(2):142-145. DOI:10.3760/cma.j.issn.2095-2848.2016.02.010.
Liu QQ, Wang ZG, Wang N, et al. Characteristics of lymph nodes on ¹⁸F-FDG PET/CT imaging in patients with non-Hodgkin's lymphoma and widespread lymph node metastases carcinoma[J]. Chin J Nucl Med Mol Imaging, 2016, 36(2):142-145. doi: 10.3760/cma.j.issn.2095-2848.2016.02.010

[6]

吕清湖, 唐明灯, 林端瑜, 等.原发鼻咽淋巴瘤与鼻咽癌的¹⁸F-FDG PET/CT诊断与鉴别[J].国际放射医学核医学杂志, 2017, 41(3):166-172. DOI:10.3760/cma.j.issn.1673-4114.2017.03.002.
Lyu QH, Tang MD, Lin DY, et al. Value of ¹⁸F-FDG PET/CT examination in the differential diagnosis of primary nasopharyngeal lymphoma and nasopharyngeal carcinoma[J]. Int J Radiat Med Nucl Med, 2017, 41(3):166-172. doi: 10.3760/cma.j.issn.1673-4114.2017.03.002

[7]

秦文琼, 高硕. PET/CT与临床预后因素在弥漫大B细胞淋巴瘤疗效评价及预后评估中的应用[J].国际放射医学核医学杂志, 2017, 41(6):437-442. DOI:10.3760/cma.j.issn.1673-4114. 2017. 06.010.
Qin WQ, Gao S. Application of PET/CT and clinical factors in the therapeutic and prognostic evaluation of diffuse large B cell lymphoma[J]. Int J Radiat Med Nucl Med, 2017, 41(6):437-442. doi: 10.3760/cma.j.issn.1673-4114.2017.06.010

[8]

Younes A, Hilden P, Coiffier B, et al. International Working Group consensus response evaluation criteria in lymphoma(RECIL 2017)[J]. Ann Oncol, 2017, 28(7):1436-1447. DOI:10.1093/annonc/mdx097.

[9]

中华医学会核医学分会PET与分子影像学组.淋巴瘤¹⁸F-FDG PET/CT显像临床应用指南(2016版)[J].中华核医学与分子影像杂志, 2016, 36(5):458-460. DOI:10.3760/cma.j.issn.2095-2848. 2016.05.017.
Imaging Group of Chinese Society of Nuclear Medicine. Clinical practice guideline of ¹⁸F-FDG PET/CT in lymphoma(2016 edition)[J]. Chin J Nucl Med Mol Imaging, 2016, 36(5):458-460. doi: 10.3760/cma.j.issn.2095-2848.2016.05.017

[10]

Jaffe ES. The 2008 WHO classification of lymphomas:implications for clinical practice and translational research[J]. Hematology Am Soc Hematol Educ Program, 2009, 2009(1):523-531. DOI:10.1182/asheducation-2009.1.523.

[11]

Finn WG, Kroft SH. New classifications for non-Hodgkin's lymphoma[J]. Cancer Treat Res, 1999, 99(99):1-26. DOI:10.1007/978-0-585-38571-6_1.

[12]

O JH, Lodge MA, Wahl RL. Practical PERCIST:A Simplified Guide to PET Response Criteria in Solid Tumors 1.0[J]. Radiology, 2016, 280(2):576-584. DOI:10.1148/radiol.2016142043.

[13]

Takata K, Miyata-Takata T, Sato Y, et al. Pathology of follicular lymphoma[J]. J Clin Exp Hematop, 2014, 54(1):3-9. DOI:10.3960/jslrt.54.3.

[14]

Fischer T, Zing NPC, Chiattone CS, et al. Transformed follicular lymphoma[J]. Ann Hematol, 2018, 97(1):17-29. DOI:10.1007/s00277-017-3151-2.

[15]

戴娜, 吴翼伟, 章斌. ¹⁸F-FDG PET/CT对不同分级和分期滤泡性淋巴瘤诊断及预后评估的价值[J].中华核医学与分子影像杂志, 2014, 34(1):23-26. DOI:10.3760/cma.j.issn.2095-2848. 2014. 01. 008.
Dai N, Wu YW, Zhang B. Grading, staging and prognosis of follicular lymphoma:the value of ¹⁸F-FDG PET/CT[J]. Chin J Nucl Med Mol Imaging, 2014, 34(1):23-26. doi: 10.3760/cma.j.issn.2095-2848.2014.01.008

[16]

丁重阳, 李天女, 孙晋, 等. ¹⁸F-FDG PET/CT在滤泡性淋巴瘤分期及疗效评价中的临床价值[J].中华核医学与分子影像杂志, 2014, 34(3):179-182. DOI:10.3760/cma.j.issn.2095-2848. 2014. 03.005.
Ding CY, Li TN, Sun J, et al. Clinical value of ¹⁸F-FDG PET/CT in clinical staging and therapeutic evaluation of follicular lymphoma[J]. Chin J Nucl Med Mol Imaging, 2014, 34(3):179-182. doi: 10.3760/cma.j.issn.2095-2848.2014.03.005

[17]

Rodriguez M, Rehn S, Ahlström H, et al. Predicting malignancy grade with PET in non-Hodgkin's lymphoma[J]. J Nucl Med, 1995, 36(10):1790-1796.

[18]

Minamimoto R, Fayad L, Advani R, et al. Diffuse large B-Cell lymphoma:prospective multicenter comparison of early interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, deauville, and PERCIST criteria for early therapeutic monitoring[J]. Radiology, 2016, 280(1):220-229. DOI:10.1148/radiol.2015150689.

[19]

Suh C, Kang YK, Roh JL, et al. Prognostic value of tumor ¹⁸F-FDG uptake in patients with untreated extranodal natural killer/T-cell lymphomas of the head and neck[J]. J Nucl Med, 2008, 49(11):1783-1789. DOI:10.2967/jnumed.108.053355.

[20]

Ahmadzadehfar H, Rodrigues M, Zakavi R, et al. Prognostic significance of the standardized uptake value of pre-therapeutic ¹⁸F-FDG PET in patients with malignant lymphoma[J]. Med Oncol, 2011, 28(4):1570-1576. DOI:10.1007/s12032-010-9584-2.

[21]

Tychyj-Pinel C, Ricard F, Fulham M, et al. PET/CT assessment in follicular lymphoma using standardized criteria:central review in the PRIMA study[J]. Eur J Nucl Med Mol Imaging, 2014, 41(3):408-415. DOI:10.1007/s00259-013-2441-8.

[22]

Angelopoulou MK, Mosa E, Pangalis GA, et al. The significance of PET/CT in the initial staging of hodgkin lymphoma:experience outside clinical trials[J]. Anticancer Res, 2017, 37(10):5727-5736. DOI:10.21873/anticanres.12011.